Related Experiment Video
Updated: Mar 19, 2026
Fluorescent Orthotopic Mouse Model of Pancreatic Cancer
Published on: September 20, 2016
Pharmacokinetics in Mouse and Comparative Effects of Frondosides in Pancreatic Cancer
Jasem Al Shemaili1, Khatija A Parekh2, Robert A Newman3
1Department of Physiology, Faculty of Medicine, United Arab Emirates University, P.O. Box 17666, Al Ain, UAE. 201617836@uaeu.ac.ae.
Abstract:
The frondosides are triterpenoid glycosides from the Atlantic sea cucumber Cucumaria frondosa. Frondoside A inhibits growth, invasion, metastases and angiogenesis and induces apoptosis in diverse cancer types, including pancreatic cancer. We compared the growth inhibitory effects of three frondosides and their aglycone and related this to the pharmocokinetics and route of administration. Frondoside A potently inhibited growth of pancreatic cancer cells with an EC50 of ~1 µM. Frondoside B was less potent (EC50 ~2.5 µM). Frondoside C and the aglycone had no effect. At 100 µg/kg, frondoside A administered to CD₂F₁ mice as an i.v. bolus, the Cpmax was 129 nM, Cltb was 6.35 mL/min/m², and half-life was 510 min. With i.p. administration the Cpmax was 18.3 nM, Cltb was 127 mL/min/m² and half-life was 840 min. Oral dosing was ineffective. Frondoside A (100 µg/kg/day i.p.) markedly inhibited growth cancer xenografts in nude mice. The same dose delivered by oral gavage had no effect. No evidence of acute toxicity was seen with frondoside A. Frondoside A is more potent inhibitor of cancer growth than other frondosides. The glycoside component is essential for bioactivity. Frondoside A is only effective when administered systemically. Based on the current and previous studies, frondoside A appears safe and may be valuable in the treatment of cancer.
Insights
Frondoside A, a compound from sea cucumbers, effectively inhibits pancreatic cancer growth. Its glycoside component is crucial, and systemic administration is necessary for efficacy, showing potential for cancer treatment.
Area of Science:
- Marine natural products
- Cancer biology
- Pharmacokinetics
Background:
- Frondosides are triterpenoid glycosides isolated from the Atlantic sea cucumber, Cucumaria frondosa.
- Frondoside A has demonstrated inhibitory effects on various cancer types, including pancreatic cancer, by affecting growth, invasion, metastasis, angiogenesis, and apoptosis.
Purpose of the Study:
- To compare the growth inhibitory effects of three frondosides and their aglycone.
- To investigate the pharmacokinetics and optimal route of administration for frondoside A.
Main Methods:
- In vitro studies using pancreatic cancer cell lines to determine EC50 values.
- In vivo studies in mice (CD₂F₁ and nude) to assess pharmacokinetics (intravenous and intraperitoneal administration) and efficacy against cancer xenografts.
- Evaluation of acute toxicity.
Main Results:
- Frondoside A potently inhibited pancreatic cancer cell growth (EC50 ~1 µM), while Frondoside B was less potent (EC50 ~2.5 µM). Frondoside C and the aglycone showed no effect.
- Systemic administration (intravenous and intraperitoneal) of Frondoside A resulted in measurable plasma concentrations and half-life, whereas oral administration was ineffective.
- Frondoside A administered intraperitoneally significantly inhibited cancer xenograft growth in mice, with no observed acute toxicity.
Conclusions:
- The glycoside component of frondosides is essential for their anti-cancer bioactivity.
- Frondoside A demonstrates superior potency and efficacy compared to other frondosides and requires systemic administration for therapeutic effect.
- Frondoside A shows promise as a safe and valuable agent for cancer treatment, particularly pancreatic cancer.
